Aytu BioPharma Inc (AYTU)

Name: Aytu BioPharma Inc Financial Statements
Creator: Quarter Results

Healthcare | Drug Manufacturers Specialty Generic

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$15.2M

Net Income

-$10.6M

Operating Margin

-13.0%

Free Cash Flow

-$5.2M

Debt / Assets

84.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Aytu BioPharma Inc (AYTU).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-03-31	2024-12-31
Revenue	15,165,000	13,888,000	18,452,000	16,221,000
Cost of Revenue	6,067,000	4,702,000	5,646,000	5,435,000
Gross Profit	9,098,000	9,186,000	12,806,000	10,786,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	11,068,000	10,246,000	9,303,000	9,721,000
Operating Expenses	11,068,000	10,690,000	9,465,000	12,481,000
Operating Income	-1,970,000	-1,504,000	2,421,000	-1,695,000
Interest Expense	560,000	516,000	-900,000	1,079,000
Income Before Tax	-10,584,000	1,965,000	3,818,000	382,000
Income Tax Expense	0	0	122,000	-283,000
Net Income	-10,584,000	1,965,000	3,994,000	788,000
Per Share
EPS	-1.05	0.21	0.01	0.13
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Aytu BioPharma Inc (AYTU).
Income Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Revenue	66,382,000	65,183,000	107,399,000	96,669,000	65,632,000
Cost of Revenue	20,551,000	16,129,000	40,767,000	44,386,000	36,432,000
Gross Profit	45,831,000	49,054,000	66,632,000	52,283,000	29,200,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	38,285,000	42,037,000	70,078,000	69,880,000	55,808,000
Operating Expenses	53,658,000	50,645,000	83,697,000	88,386,000	67,440,000
Operating Income	-7,827,000	-1,591,000	-17,065,000	37,215,000	-58,870,000
Interest Expense	3,703,000	4,792,000	4,963,000	147,498,000	0
Income Before Tax	-13,745,000	-10,378,000	-17,051,000	-110,283,000	-58,030,000
Income Tax Expense	437,000	2,142,000	-57,000	-110,000	259,000
Net Income	-13,562,000	-15,844,000	-17,051,000	-110,173,000	-58,289,000
Per Share
EPS	-2.16	-2.86	-5.11	-1,499.10	-0.17
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Aytu BioPharma Inc (AYTU).
Balance Sheet (Quarterly)	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Assets
Cash and Cash Equivalents	30,952,000	20,006,000	22,985,000	19,360,000
Short Term Investments	0	0	0	0
Net Receivables	31,155,000	23,526,000	28,937,000	21,712,000
Inventory	11,434,000	12,141,000	11,995,000	10,849,000
Total Current Assets	79,179,000	61,891,000	72,832,000	59,929,000
Property Plant Equipment	1,593,000	1,522,000	3,869,000	6,296,000
Goodwill and Intangibles	42,201,000	52,453,000	58,970,000	70,632,000
Total Assets	124,177,000	118,857,000	136,463,000	137,623,000
Liabilities
Account Payables	10,601,000	10,314,000	13,478,000	10,987,000
Short Term Debt	11,057,000	4,964,000	85,000	3,909,000
Total Current Liabilities	63,064,000	62,228,000	69,015,000	64,442,000
Long Term Debt	11,880,000	11,454,000	14,713,000	14,279,000
Total Liabilities	105,211,000	91,141,000	97,106,000	91,531,000
Shareholders Equity
Retained Earnings	-333,535,000	-319,973,000	-304,129,000	-288,472,000
Total Shareholders Equity	18,966,000	27,716,000	39,357,000	46,092,000

Balance sheet annual history for Aytu BioPharma Inc (AYTU).
Balance Sheet (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Assets
Cash and Cash Equivalents	30,952,000	20,006,000	22,985,000	19,360,000	49,649,000
Short Term Investments	0	0	0	0	0
Net Receivables	31,155,000	23,526,000	28,937,000	21,712,000	28,176,000
Inventory	11,434,000	12,141,000	11,995,000	10,849,000	16,339,000
Total Current Assets	79,179,000	61,891,000	72,832,000	59,929,000	105,234,000
Property Plant Equipment	1,593,000	1,522,000	3,869,000	6,296,000	8,703,000
Goodwill and Intangibles	42,201,000	52,453,000	58,970,000	70,632,000	151,266,000
Total Assets	124,177,000	118,857,000	136,463,000	137,623,000	265,668,000
Liabilities
Account Payables	10,601,000	10,314,000	13,478,000	10,987,000	19,255,000
Short Term Debt	11,057,000	4,964,000	85,000	3,909,000	25,542,000
Total Current Liabilities	63,064,000	62,228,000	69,015,000	64,442,000	109,438,000
Long Term Debt	11,880,000	11,454,000	14,713,000	14,279,000	2,804,000
Total Liabilities	105,211,000	91,141,000	97,106,000	91,531,000	128,100,000
Shareholders Equity
Retained Earnings	-333,535,000	-319,973,000	-304,129,000	-288,472,000	-178,299,000
Total Shareholders Equity	18,966,000	27,716,000	39,357,000	46,092,000	137,568,000

Cash flow quarterly history for Aytu BioPharma Inc (AYTU).
Cash Flow Statement (Quarterly)	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Operating Activities
Net Income	-13,562,000	-15,844,000	-17,051,000	-110,173,000
Depreciation & Amortization	5,377,000	6,725,000	8,815,000	10,251,000
Stock Based Compensation	576,000	2,373,000	6,046,000	5,248,000
Change in Working Capital	-5,733,000	-4,660,000	-5,798,000	-10,863,000
Operating Cash Flow	-1,937,000	-1,388,000	-5,129,000	-28,823,000
Investing Activities
Capital Expenditure	-3,228,000	-329,000	0	0
Investments	-228,000	-329,000	0	0
Investing Cash Flow	-2,560,000	-329,000	-117,000	-3,248,000
Financing Activities
Debt Repayment	6,668,000	-1,890,000	-2,346,000	-172,458,000
Common Stock Issued/Repurchased	14,840,000	3,467,000	15,575,000	11,694,000
Dividends Paid	0	0	0	0
Financing Cash Flow	15,443,000	-1,262,000	8,871,000	1,530,000
Summary
Free Cash Flow	-5,165,000	-1,717,000	-5,129,000	-28,823,000
Net Change in Cash	10,946,000	-2,979,000	3,625,000	-30,541,000

Cash flow annual history for Aytu BioPharma Inc (AYTU).
Cash Flow Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Operating Activities
Net Income	-13,562,000	-15,844,000	-17,051,000	-110,173,000	-58,289,000
Depreciation & Amortization	5,377,000	6,725,000	8,815,000	10,251,000	9,201,000
Stock Based Compensation	576,000	2,373,000	6,046,000	5,248,000	3,574,000
Change in Working Capital	-5,733,000	-4,660,000	-5,798,000	-10,863,000	1,681,000
Operating Cash Flow	-1,937,000	-1,388,000	-5,129,000	-28,823,000	-25,964,000
Investing Activities
Capital Expenditure	-3,228,000	-329,000	0	0	0
Investments	-228,000	-329,000	0	0	0
Investing Cash Flow	-2,560,000	-329,000	-117,000	-3,248,000	-2,782,000
Financing Activities
Debt Repayment	6,668,000	-1,890,000	-2,346,000	-172,458,000	-54,947,000
Common Stock Issued/Repurchased	14,840,000	3,467,000	15,575,000	11,694,000	45,051,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	15,443,000	-1,262,000	8,871,000	1,530,000	30,314,000
Summary
Free Cash Flow	-5,165,000	-1,717,000	-5,129,000	-28,823,000	-25,964,000
Net Change in Cash	10,946,000	-2,979,000	3,625,000	-30,541,000	1,568,000